UBS lowered the firm’s price target on Certara (CERT) to $10 from $15 and keeps a Buy rating on the shares. The firm says the company’s Q4 results and 2026 guidance challenge the Buy thesis on the shares. Certara reported a Q4 services miss and deceleration in software bookings, the analyst tells investors in a research note. However, UBS believes the company remains “uniquely positioned” in model-informed drug development.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara: Capitalizing on Growing Biosimulation Adoption Despite Near-Term Software Headwinds
- Certara downgraded to Equal Weight from Overweight at Barclays
- Certara announces Simcyp Simulator predictions accepted by U.S. FDA
- Certara Earnings Call: Software Strength Amid Transition
- Craig-Hallum downgrades Certara to Hold following ‘mediocre quarter’